naltrexone and varenicline

naltrexone has been researched along with varenicline in 30 studies

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (13.33)29.6817
2010's17 (56.67)24.3611
2020's9 (30.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Gilbert, M; Laustsen, G; Wimett, L1
Bartlett, SE; Holgate, J; Richards, JK; Simms, JA; Steensland, P1
Tyndale, R1
Kuehn, BM1
Brody, A; Courtney, KE; Ghahremani, DG; London, ED; Miotto, K; Ray, LA2
Bujarski, S; Ray, LA1
Fisher, DC; Fletcher, PJ; Guy, EG; Higgins, GA1
Lieb, M; Soyka, M1
Bujarski, S; Green, R; Hartwell, E; Ray, LA; Roche, DJ1
Klein, JW1
Dilley, JE; Filosa, NJ; Fischer, SM; Froehlich, JC; Nicholson, ER; Rademacher, LC; Smith, TN2
Lyon, J1
Bardo, MT; Bell, RL; Crooks, PA; Dwoskin, LP; Maggio, SE; Nixon, K; Prendergast, MA; Saunders, MA; Zheng, G1
Achenbach, C; Akanbi, MO; Bilaver, LA; Carroll, AJ; Hitsman, B; Jordan, N; McHugh, MC; Murphy, R; O'Dwyer, LC1
Lim, AC; Ray, LA; Roche, DJO1
Hauser, SR; Knight, CP; McBride, WJ; Pratt, LA; Rodd, ZA; Waeiss, RA1
Anton, RF; Falk, DE; Fertig, J; Hasin, DS; Johnson, B; Kranzler, HR; Litten, RZ; Mann, KF; Meulien, D; O'Malley, SS; Ryan, M; Slater, M; Witkiewitz, K1
Ayers, C; Chan, B; Freeman, M; Kansagara, D; Kondo, K; Montgomery, J; Paynter, R1
Bardo, MT; Chandler, CM; Maggio, SE; Nixon, K; Peng, H1
Kenny, PJ; O'Brien, CP; Pierce, RC; Swinford-Jackson, SE; Unterwald, EM; Vanderschuren, LJMJ1
Grodin, EN; Ho, D; Ray, LA; Towns, B1
Enders, C; Green, R; Grodin, EN; Hartwell, E; Ho, D; Leventhal, AM; Li, G; Lim, A; Meredith, L; Miotto, K; Nieto, SJ; Ray, LA; Shoptaw, S; Venegas, A1
Burnette, EM; Green, R; Grodin, EN; Lim, AC; Miotto, K; Ray, LA1
Kalin, NH1
Green, R; Montoya, AK; Ray, LA1
Green, R; Ray, LA; Roche, DJO1
Enders, CK; Nieto, SJ; O'Malley, SS; Ray, LA; Witkiewitz, K1

Reviews

5 review(s) available for naltrexone and varenicline

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Recent Developments in Pharmacotherapy of Alcoholism.
    Pharmacopsychiatry, 2015, Volume: 48, Issue:4-5

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline

2015
Pharmacotherapy for Substance Use Disorders.
    The Medical clinics of North America, 2016, Volume: 100, Issue:4

    Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline

2016
The efficacy of smoking cessation interventions in low- and middle-income countries: a systematic review and meta-analysis.
    Addiction (Abingdon, England), 2019, Volume: 114, Issue:4

    Topics: Adult; Behavior Therapy; Bupropion; Cigarette Smoking; Clonidine; Counseling; Developing Countries; Humans; Mobile Applications; Naltrexone; Nortriptyline; Randomized Controlled Trials as Topic; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Varenicline

2019
Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis.
    Addiction (Abingdon, England), 2019, Volume: 114, Issue:12

    Topics: Amphetamine-Related Disorders; Anticonvulsants; Antidepressive Agents; Antipyretics; Drug Therapy; Humans; Methylphenidate; Naltrexone; Outcome Assessment, Health Care; Varenicline

2019

Trials

9 trial(s) available for naltrexone and varenicline

ArticleYear
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
    Psychopharmacology, 2014, Volume: 231, Issue:19

    Topics: Adult; Alcohol Drinking; Benzazepines; Craving; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult

2014
Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
    The American journal of drug and alcohol abuse, 2015, Volume: 41, Issue:1

    Topics: Adult; Alcoholism; Benzazepines; Brain; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Treatment Outcome; Varenicline

2015
Negative affect is associated with alcohol, but not cigarette use in heavy drinking smokers.
    Addictive behaviors, 2014, Volume: 39, Issue:12

    Topics: Adult; Affect; Alcohol-Related Disorders; Benzazepines; Comorbidity; Craving; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Psychiatric Status Rating Scales; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult

2014
Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.
    Pharmacology, biochemistry, and behavior, 2015, Volume: 134

    Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Humans; Male; Naltrexone; Smoking; Smoking Cessation; Varenicline

2015
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    JAMA psychiatry, 2019, 04-01, Volume: 76, Issue:4

    Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Risk Assessment; Topiramate; Varenicline

2019
A novel human laboratory model for screening medications for alcohol use disorder.
    Trials, 2020, Nov-23, Volume: 21, Issue:1

    Topics: Alcohol Drinking; Alcoholism; Humans; Laboratories; Naltrexone; Varenicline

2020
Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.
    The American journal of psychiatry, 2021, 09-01, Volume: 178, Issue:9

    Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Cholinergic Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Smoking Cessation Agents; Varenicline

2021
The Effects of Menstrual Cycle Hormones on Responses to Varenicline and Naltrexone Among Female Heavy Drinking Smokers.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2022, Sep-10, Volume: 57, Issue:5

    Topics: Double-Blind Method; Female; Hormones; Humans; Male; Menstrual Cycle; Naltrexone; Smokers; Varenicline

2022
Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Alcoholism, clinical and experimental research, 2022, Volume: 46, Issue:12

    Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Naltrexone; Treatment Outcome; Varenicline; World Health Organization

2022

Other Studies

16 other study(ies) available for naltrexone and varenicline

ArticleYear
Drug approvals.
    The Nurse practitioner, 2007, Volume: 32, Issue:2

    Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline

2007
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Jul-24, Volume: 104, Issue:30

    Topics: Animals; Appetite; Behavior, Addictive; Behavior, Animal; Benzazepines; Ethanol; Male; Naltrexone; Nicotinic Agonists; Quinoxalines; Rats; Receptors, Nicotinic; Sensitivity and Specificity; Sucrose; Varenicline; Water

2007
Drug addiction: a critical problem calling for novel solutions.
    Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:4

    Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline

2008
Findings on alcohol dependence point to promising avenues for targeted therapies.
    JAMA, 2009, Apr-22, Volume: 301, Issue:16

    Topics: Alcoholism; Animals; Benzazepines; Humans; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Nicotinic Agonists; Pharmacogenetics; Pyridines; Quinoxalines; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Stress, Psychological; Triazoles; Varenicline

2009
Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats.
    Behavioural pharmacology, 2014, Volume: 25, Issue:8

    Topics: Animals; Benzazepines; Bupropion; Cholinergic Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Narcotic Antagonists; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Reinforcement, Psychology; Varenicline

2014
Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.
    Alcoholism, clinical and experimental research, 2016, Volume: 40, Issue:9

    Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Rats; Rodentia; Treatment Outcome; Varenicline

2016
A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking.
    Alcoholism, clinical and experimental research, 2017, Volume: 41, Issue:3

    Topics: Alcohol Drinking; Animals; Drug Therapy, Combination; Genetic Predisposition to Disease; Male; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Rats; Varenicline

2017
More Treatments on Deck for Alcohol Use Disorder.
    JAMA, 2017, Jun-13, Volume: 317, Issue:22

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline

2017
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.
    Drug and alcohol dependence, 2018, 12-01, Volume: 193

    Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Disease Models, Animal; Ethanol; Female; Naltrexone; Nicotine; Nicotinic Antagonists; Picolines; Pyridinium Compounds; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Varenicline

2018
Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
    Journal of studies on alcohol and drugs, 2018, Volume: 79, Issue:6

    Topics: Adult; Alcohol Drinking; Alcoholism; Cigarette Smoking; Craving; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Smokers; Smoking Cessation; Stress, Psychological; Varenicline; Young Adult

2018
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.
    Psychopharmacology, 2019, Volume: 236, Issue:6

    Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Injections, Subcutaneous; Naltrexone; Nicotine; Random Allocation; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline

2019
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.
    Drug and alcohol dependence, 2020, 07-01, Volume: 212

    Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Male; Naltrexone; Nicotine; Rats; Rats, Sprague-Dawley; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline

2020
The Persistent Challenge of Developing Addiction Pharmacotherapies.
    Cold Spring Harbor perspectives in medicine, 2021, 11-01, Volume: 11, Issue:11

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-Related Disorders; Drug Therapy; Humans; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Smoking Cessation Agents; Substance-Related Disorders; Varenicline

2021
Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.
    Drug and alcohol dependence, 2021, 08-01, Volume: 225

    Topics: Alcohol Drinking; Alcoholism; Cues; Double-Blind Method; Humans; Naltrexone; Smokers; Varenicline

2021
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities.
    The American journal of psychiatry, 2021, 09-01, Volume: 178, Issue:9

    Topics: Alcoholism; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Patient Outcome Assessment; Schizophrenia; Smoking; Varenicline

2021
The relationship between drinking and smoking in a clinical trial for smoking cessation and drinking reduction.
    Experimental and clinical psychopharmacology, 2022, Volume: 30, Issue:6

    Topics: Alcohol Drinking; Naltrexone; Smoking; Smoking Cessation; Treatment Outcome; Varenicline

2022